Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 246

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials

Open access
Hershman, Dawn L., Till, Cathee, Wright, Jason D., Awad, Danielle, Ramsey, Scott D., Barlow, William E., Minasian, Lori M., Unger, Joseph · 2016 · Journal of Clinical Oncology

Abstract

Background: Neuropathy is a debilitating toxicity associated with various chemotherapy agents. We evaluated the association between common comorbid conditions and the development of peripheral neuropathy in patients treated with taxane-based chemotherapy. Methods: We examined the Southwest Oncology Group database to identify phase II and III trials that included taxane therapy from 1999 to 2011. We linked the Southwest Oncology Group clinical records to Medicare claims data according to Social Security number, sex, and date of birth. The following disease conditions potentially associated with peripheral neuropathy were evaluated: diabetes, hypothyroidism, hypercholesterolemia, hypertension, varicella zoster, peripheral vascular disease, and autoimmune diseases. Multivariate logistic regression was used to model the odds of experiencing grade 2 to 4 neuropathy. Results: A total of 1,401 patients from 23 studies were included in the analysis. Patients receiving paclitaxel were more likely to experience grade 2 to 4 neuropathy compared with docetaxel (25% v 12%, respectively; OR, 2.20; 95% CI, 1.52 to 3.18; P < .001). The inclusion of a platinum agent was also associated with greater neuropathy (OR, 1.68; 95% CI, 1.18 to 2.40; P = .004). For each increase in age of 1 year, the odds of neuropathy increased 4% (P = .006). Patients with complications from diabetes had more than twice the odds of having neuropathy (OR, 2.13; 95% CI, 1.31 to 3.46; P = .002) compared with patients with no diabetes. In contrast, patients with autoimmune disease were half as likely to experience neuropathy (OR, 0.49; 95% CI, 0.24 to 1.02; P = .06). The other conditions were not associated with neuropathy. Conclusion: We found that in addition to drug-related factors, age and history of diabetes were independent predictors of the development of chemotherapy-induced peripheral neuropathy. Interestingly, we also observed that a history of autoimmune disease was associated with reduced odds of neuropathy. Patients with diabetic complications may choose to avoid paclitaxel or taxane plus platinum combination therapies if other efficacious options exist.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2015.66.2346

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 22

  1. 10.1007/s10549-010-1278-0 · DOI · Paper page
  2. 10.1200/JCO.2005.04.0543 · DOI · Paper page
  3. 10.1007/978-3-319-16366-6_6 · DOI
  4. 10.1200/JCO.2013.54.0914 · DOI · Paper page
  5. 10.1200/JCO.1993.11.10.2010 · DOI · Paper page
  6. Rowinsky EK, 1993, Semin Oncol, 20, 1
  7. 10.1158/1078-0432.CCR-15-0586 · DOI
  8. 10.1200/JCO.2011.39.8446 · DOI
  9. 10.1006/gyno.1996.0090 · DOI
  10. 10.6004/jnccn.2015.0057 · doi:10.6004/jnccn.2015.0057
  11. 10.1038/ncpneuro0504 · DOI · Paper page
  12. 10.1056/NEJM199507133330203 · DOI · Paper page
  13. Kanbayashi Y, 2013, Anticancer Res, 33, 1153
  14. 10.1007/s10549-011-1671-3 · DOI
  15. 10.1177/1077558707305409 · DOI · Paper page
  16. 10.1055/s-0034-1390391 · DOI
  17. 10.1007/s00415-014-7354-3 · doi:10.1007/s00415-014-7354-3
  18. 10.1016/j.jneuroim.2014.01.012 · doi:10.1016/j.jneuroim.2014.01.012
  19. 10.1016/j.cyto.2012.03.027 · DOI · Paper page
  20. 10.1213/ANE.0b013e31824b0191 · DOI
  21. 10.1002/cncr.21999 · DOI
  22. 10.1093/jnci/djj305 · DOI · Paper page

Cited by

See all 246

Metadata

Authors
Hershman, D. L., Till, C., Wright, J. D., Awad, D., Ramsey, S. D., Barlow, W. E., Minasian, L. M., & Unger, J.
Venue
Journal of Clinical Oncology
Published
2016-09-01
Volume
34
Issue
25
Pages
3014-3022
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2471488931
Cited by
246
References
1
FWCI
10.97
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. https://app.cochat.ai/papers/10.1200/jco.2015.66.2346
The paper
Hershman, D. L., Till, C., Wright, J. D., Awad, D., Ramsey, S. D., Barlow, W. E., Minasian, L. M., & Unger, J. (2016). Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.66.2346

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.